HLA-DRB1 anticorps
-
- Antigène Voir toutes HLA-DRB1 Anticorps
- HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
-
Reactivité
- Humain, Souris, Rat
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp HLA-DRB1 est non-conjugé
-
Application
- Western Blotting (WB), ELISA
- Specificité
- HLA-DRB1 Antibody detects endogenous levels of total HLA-DRB1
- Réactivité croisée
- Humain, Souris, Rat (Rattus)
- Purification
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
- Immunogène
- A synthesized peptide derived from human HLA-DRB1
- Isotype
- IgG
- Top Product
- Discover our top product HLA-DRB1 Anticorps primaire
-
-
- Indications d'application
- WB 1:1000-3000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20 °C.Stable for 12 months from date of receipt
- Date de péremption
- 12 months
-
- Antigène
- HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
- Autre désignation
- HLA-DRB1 (HLA-DRB1 Produits)
- Synonymes
- anticorps MGC108235, anticorps DRB1, anticorps DRw10, anticorps HLA-DR1B, anticorps HLA-DRB, anticorps SS1, anticorps major histocompatibility complex, class II, DR beta 1, anticorps hla-drb1, anticorps HLA-DRB1
- Sujet
-
Description: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Gene: HLA-DRB1
- Poids moléculaire
- 29 kDa
- ID gène
- 3123
- UniProt
- P01911
- Pathways
- TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-